This $77 Billion Hedge Fund Company Bought Coca-Cola, Pfizer, and Fifth Third Bank
The latest 13F season is here, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling.
For example, consider Citadel Advisors, founded and led by Kenneth Griffin. It's one of the biggest hedge fund companies around, with a reportable stock portfolio totaling $76.8 billion in value as of Dec. 31, 2013. According to the folks at Insider Monkey, Griffin and his team use "a combination of advanced computer code, complicated financial algorithms and secrecy. Griffin was using quantitative, technology-based methods before many other firms had cell phones."
Citadel Advisors' latest 13F report shows that it boosted its positions in Fifth Third Bancorp , Coca-Cola , and Pfizer .
Cincinnati-based Fifth Third Bancorp has been responding to customer preferences in part by experimenting with more self-service features in branches, such as advanced ATMs that do more than take or dispense money. Bank of America Merrill Lynch analyst Erika Najarian upgraded Fifth Third stock to buy last month, citing its valuation and seeing it as a defensive investment. The company's fourth quarter featured earnings per share up 22% from year-ago levels and record full-year net income. Fifth Third Bancorp stock yields 2.1%.
Coca-Cola stock underperformed the market in 2013, facing weak international growth and challenges from regulators and health advocates. Its last quarter was disappointing, with revenue and earnings lower than year-ago levels -- though market share in soda has been steadily growing in recent years. The company has outlined five strategic priorities, including accelerating sparkling-beverage growth, expanding its portfolio, and winning at the point of sale. Coca-Cola stock yields 3.2%.
Pfizer stock also yields 3.2%. As with other big pharmaceutical companies, its blockbuster drugs face patent expirations sooner or later. Pfizer's 2014 and 2015 revenue is expected to pull back because of expirations, therefore its pipeline of new offerings is paramount. Some treatments generating optimism target breast cancer and pneumonia. There's also hope that its drug Lyrica might be approved to treat restless legs syndrome. Pfizer's fourth quarter featured shrinking sales of Viagra and Lipitor due to patent expirations abroad and at home, respectively.
More Dividend Payers to Reward You
Dividend stocks as a group handily outperform their non-dividend-paying brethren.With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.
The article This $77 Billion Hedge Fund Company Bought Coca-Cola, Pfizer, and Fifth Third Bank originally appeared on Fool.com.Selena Maranjian, whom you can follow on Twitter,owns shares of Coca-Cola. The Motley Fool recommends Coca-Cola. The Motley Fool owns shares of Coca-Cola and Fifth Third Bancorp and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.